Agenus (AGEN) Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AGEN shares.
View AGEN analyst ratings or view top-rated stocks.

4 brokerages have issued twelve-month price targets for Agenus' stock. Their AGEN share price forecasts range from $5.00 to $8.30. On average, they predict the company's share price to reach $7.33 in the next year. This suggests a possible upside of 390.0% from the stock's current price.
View analysts price targets for AGEN or view top-rated stocks among Wall Street analysts.

Agenus' stock was trading at $2.40 at the start of the year. Since then, AGEN stock has decreased by 37.7% and is now trading at $1.4950.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our AGEN earnings forecast.

Agenus Inc. (NASDAQ:AGEN) posted its quarterly earnings data on Tuesday, March, 14th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.02. The biotechnology company earned $28.39 million during the quarter, compared to analysts' expectations of $17.83 million. Agenus had a negative trailing twelve-month return on equity of 1,159.04% and a negative net margin of 264.19%.

ETFs with the largest weight of Agenus (NASDAQ:AGEN) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), WisdomTree BioRevolution Fund (WDNA), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Future Gen 200 ETF (QQQS), ALPS Medical Breakthroughs ETF (SBIO) and Principal Healthcare Innovators ETF (BTEC).

2 employees have rated Agenus Chief Executive Officer Garo H. Armen on Glassdoor.com. Garo H. Armen has an approval rating of 56% among the company's employees. This puts Garo H. Armen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Agenus investors own include (ROSG) (ROSG), Exelixis (EXEL), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), OPKO Health (OPK), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Gilead Sciences (GILD), Matinas BioPharma (MTNB) and RedHill Biopharma (RDHL).

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

Agenus' stock is owned by a number of institutional and retail investors. Top institutional investors include State Street Corp (7.50%), BlackRock Inc. (7.05%), Bank of America Corp DE (2.40%), Geode Capital Management LLC (1.58%), Renaissance Technologies LLC (1.34%) and Charles Schwab Investment Management Inc. (0.64%). Insiders that own company stock include Agenus Inc, Christine M Klaskin, Corp Incyte, Garo H Armen and Steven J O'day.
View institutional ownership trends.

Shares of AGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AGEN stock can currently be purchased for approximately $1.50.

Agenus (NASDAQ:AGEN) has a market capitalization of $521.58 million and generates $98.02 million in revenue each year. The biotechnology company earns $-220,070,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis.

The company employs 441 workers across the globe.

Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The official website for the company is agenusbio.com. The biotechnology company can be reached via phone at (781) 674-4400, via email at investor@agenusbio.com, or via fax at 781-674-4200.